Author

Akul Naik

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:deep learning· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:protein folding & dynamics· 1 Assay:proteomics· 1

Frequent Co-Authors

Arun P. WiitaiD· 2 shared Abhilash BarpandaiD· 1 shared Adila IzgutdinaiD· 1 shared Amit VermaiD· 1 shared Amrik S. KangiD· 1 shared Andrej ŠaliiD· 1 shared Antonio ValeriiD· 1 shared Arthur O. ZalevskyiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Arun P. WiitaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Extending structural surfaceomics to identify aberrant conformations of tumor surface proteins as potential immunotherapy targets

Audrey Kishishita, Sabine Cismoski, Tianna Grant, Rucha Deo, Sanjana Prudhvi, Catherine Sue, Abhilash Barpanda, Clinton Yu, Sanjyot Vinayak Shenoy, Sarah Berman, Audrey G. Reeves, Haolong Li, Tianyi Liu, Akul Naik, Deeptarup Biswas, , Arun P. Wiita

This paper expands structural surfaceomics to identify cancer-specific protein conformations across multiple tumor models, revealing potential immunotherapy targets through crosslinking mass spectrometry and structural modeling.

bioRxiv · May 18, 2026 · PreprintCancer Biology

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies

Adila Izgutdina, Tasfia Rashid, William C. Temple, Sarah Aminov, Bonell Patiño-Escobar, Sujata B. Walunj, Huimin Geng, Hiroyuki Takamatsu, Daniel Gil-Alós, Amrik S. Kang, Emilio Ramos, Szu‐Ying Chen, Haley Johnson, Matthew A. Nix, Akul Naik, , Arun P. Wiita

This study shows that affinity-matured CD72-targeting nanobody CAR T-cells improve in vitro efficacy against CD72-low tumors but show limited in vivo benefit, while CD72 expression remains stable after CD19 resistance in B-cell malignancies.

Journal for ImmunoTherapy of Cancer · Dec 1, 2025Peer-reviewedImmunology